

A survey evaluating blood pressure control and treatment adherence in the general hypertensive population with concomitant hypercholesterolemia or stable coronary artery disease

Submission date 12/07/2017	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 13/09/2017	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 15/04/2019	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Hypertension (high blood pressure) and hypercholesterolemia (high blood cholesterol) are two of the most commonly co-occurring cardiovascular (heart disease) risk factors, with 338 million patients worldwide with both conditions. Reductions in blood pressure or total cholesterol have been shown to reduce the risk of cardiovascular disease. However, blood pressure control in these patients is difficult, with a major contributing factor being poor adherence to treatment, which has been shown to be significantly improved by the use of single-pill combinations. The aim of this study is to assess blood pressure control in hypertensive patients with hypercholesterolemia or stable coronary artery disease.

Who can participate?

Hypertensive outpatients aged over 18 with hypercholesterolemia or stable coronary artery disease

What does the study involve?

Participants' medical history, other diseases and medications are assessed using a questionnaire. Treatment adherence is assessed by asking about their current use of antihypertensive medication and statins.

What are the possible benefits and risks of participating?

Participation in the study will enable a better understanding of how patients with high blood pressure are characterized, treated and managed. No additional investigations or treatments are required in order to collect the data, therefore there is no risk to the participants.

Where is the study run from?

University Hospital Leipzig (Germany)

When is the study starting and how long is it expected to run for?
March 2017 to August 2017

Who is funding the study?
Servier International (France)

Who is the main contact?
1. Ms Andrea Korzinek
2. Prof. Ulrich Laufs

Contact information

Type(s)

Public

Contact name

Ms Andrea Korzinek

Contact details

Elsenheimerstr. 53
Munich
Germany
80687

Type(s)

Scientific

Contact name

Prof Ulrich Laufs

Contact details

University Hospital Leipzig
Liebigstr. 20
Leipzig
Germany
04103

Additional identifiers

Protocol serial number

DIM-05153-001

Study information

Scientific Title

A survey evaluating blood pressure control and treatment adherence in the general hypertensive population with concomitant hypercholesterolemia or stable coronary artery disease: an observational cross-sectional study

Study objectives

The primary objective is to evaluate blood pressure control in hypertensive patients with concomitant hypercholesterolemia or stable coronary artery disease (stable CAD).

The secondary objective is to evaluate treatment adherence using the Morisky Medication Adherence Scale-8 (MMAS-8) self-assessment questionnaire and number of antihypertensive pills prescribed.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Commission at the Medical Association of the Saarland (Germany), 25/01/2017, ref: ID: 307 /16

Study design

Single-visit multicentric non-interventional cross-sectional survey

Primary study design

Observational

Study type(s)

Screening

Health condition(s) or problem(s) studied

Hypertensive outpatients with concomitant hypercholesterolemia or stable coronary artery disease

Interventions

Medical history, concomitant diseases and medication will be documented by a questionnaire. Treatment adherence will be assessed by self-reported current use of antihypertensive medication and statins using the MMAS-8.

Intervention Type

Other

Primary outcome(s)

Blood pressure control, evaluated using office blood pressure values and blood pressure targets corresponding to the latest ESH/ESC Guidelines for the management of arterial hypertension 2013. One visit per patient (snapshot, no follow-up data)

Key secondary outcome(s)

Treatment adherence and number of antihypertensive pills prescribed, evaluated using the Morisky Medication Adherence Scale-8 (MMAS-8) self-assessment questionnaire. One visit per patient (snapshot, no follow-up data)

Completion date

01/12/2017

Eligibility

Key inclusion criteria

1. Age \geq 18 years
2. Confirmed (in medical records) diagnosis of hypertension
3. Confirmed (in medical records) diagnosis of hypercholesterolemia or stable coronary artery disease
4. Prescription of \geq 1 antihypertensive medication
5. Prescription of a statin
6. Signed consent form

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

3188

Key exclusion criteria

Patients hospitalized for cardiovascular diseases in the last 3 months (including revascularization)

Date of first enrolment

15/03/2017

Date of final enrolment

31/08/2017

Locations**Countries of recruitment**

Germany

Study participating centre

University Hospital Leipzig

Germany

04103

Sponsor information

Organisation

Servier International

ROR

<https://ror.org/034e7c066>

Funder(s)

Funder type

Industry

Funder Name

Servier International

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available. The data required for the statistical evaluation of this survey will be transmitted in pseudonymised (encrypted) form to Servier Deutschland GmbH and to a data processing office commissioned by Servier Deutschland GmbH, called PHARMALOG Institut für klinische Forschung GmbH (Neumarkter Strasse 18, 81673 Munich) as well as in anonymized form to Servier International 35 rue de Verdun, 92285 Suresnes cedex, and they will be stored at these three locations for a maximum of 10 years. This will take place in accordance with the data protection regulations in force in Germany.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	18/12/2018	15/04/2019	Yes	No